AGE-SPECIFIC BLASTULATION RATES IN EMBRYO CRYOPRESERVATION CYCLES YIELDING A CRYOPRESERVED BLASTOCYST

BackgroundOvarian reserve and normal oocyte ploidy are inversely correlated to maternal age. However, the effects of ovarian aging on blastocyst conversion rates is not clearly described in literature. Age-specific data this topic would be useful when counseling patients after an embryo cryopreservation cycle.ObjectiveTo determine blastulation cycles which yield at least one cryopreserved usable blastocystMaterials MethodsWe conducted a retrospective cohort study performed academic hospital setting. Patients who underwent their first stimulation cycle with upfront blastocysts our IVF center between 01/01/2014 08/31/2020 were included. stratified by age (Table). Exclusion criteria included failure develop blastocyst, insemination surgically retrieved sperm, IVM-ICSI cycles. The primary outcome was rate (defined as number blastocysts/number fertilized oocytes (2pn)); secondary outcomes mature fertilization rate. A nonparametric test for trend across groups outcome, statistical significance denoted p-value <0.05.ResultsA total 3,280 met inclusion criteria. median (IQR) AMH (ng/mL) linearly decreased increasing from 3.5 (1.9-6.1) <30 years 1.1 (0.8-1.6) ≥45 years. ICSI >90% each patient year. Among all patients, antagonist-based protocol used Total gonadotropin dose (units) increased 1850 (1845-2650) 4438 (3038-5250) retrieved, oocytes, (2pn) 18 (12-24), 14 (10-20), 11 (8-16), 7 (4-11) 8 (4-13), 6 (4-10), 5 (3-7), 2 (1-2) (p<0.001 outcomes; Table). 68.4 (53.3-87.5) 50.0 (37.5-66.7) (p<0.001).ConclusionsOverall, decreases In cohort, even women years, over half developed stage. affected This information completing compare results expected year Importantly, represents good prognosis population that must applied do successfully stage.Financial SupportNoneReferencesTabled 1Table. association oocyte/embryo development ratesAge (years)Oocytes retrievedMature oocytesFertilized oocytesCryopreserved blastocystsBlastocyst (%)<30 (n=155)18 (12-24)14 (10-20)11 (8-16)7 (4-11)68.4 (53.3-87.5)30 (n=88)19 (11-26)14 (9-20)12 (7-16)7 (4-10)67.3 (50.0-85.2)31 (n=139)17 (12-22)13 (9-19)10 (4-10)71.4 (57.1-83.3)32 (n=161)18 (4-11)71.4 (53.9-83.3)33 (n=157)16 (11-22)12 (8-18)10 (6-15)6 (3-10)66.7 (50.0-83.3)34 (n=208)15 (11-24)12 (9-17)10 (7-14)6 (4-10)66.7 (52.9-85.7)35 (n=257)15 (10-19)11 (8-16)9 (6-13)6 (4-9)71.4 (52.9-85.7)36 (n=257)14 (10-21)11 (7-17)9 (6-13)5 (3-8)66.7 (50.0-80.0)37 (n=289)13 (10-19)10 (7-15)8 (5-12)5 (50.0-83.3)38 (n=276)13 (9-19)11 (2-8)66.7 (50.0-81.8)39 (n=272)12 (8-17)9 (6-13)7 (5-11)5 (3-7)66.7 (50.0-83.3)40 (n=297)12 (6-13)8 (50.0-82.6)41 (n=230)11 (7-16)8 (5-12)6 (4-10)4 (2-6)62.5 (50.0-80.0)42 (n=204)10 (6-12)6 (4-9)3 (2-5)57.1 (42.9-75.0)43 (n=153)11 (6-15)9 (5-12)7 (42.9-75.0)44 (n=77)9 (6-12)7 (5-10)6 (3-8)2 (1-4)50.0 (37.5-66.7)≥45 (n=60)8 (4-13)6 (4-10)5 (3-7)2 (1-3)50.0 (37.5-66.7)Test linear trendp<0.001p<0.001p<0.001p<0.001p<0.001Data Open table new tab cycle. Ovarian ObjectiveTo To Materials <0.05. We ResultsA (p<0.001). ConclusionsOverall, Overall,